150 related articles for article (PubMed ID: 12385405)
1. Further enhancement of the safety of human plasma derivatives.
Lamb C
Transfusion; 2002 Aug; 42(8):973-4. PubMed ID: 12385405
[No Abstract] [Full Text] [Related]
2. Genomic screening for blood-borne viruses in transfusion settings.
Lee HH; Allain JP
Vox Sang; 1998; 74 Suppl 2():119-23. PubMed ID: 9704433
[No Abstract] [Full Text] [Related]
3. [Viral safety measures of plasma for transfusion and applicability in Spain].
Pereira A
Med Clin (Barc); 2007 Oct; 129(12):458-68. PubMed ID: 17953912
[No Abstract] [Full Text] [Related]
4. Emerging viruses and transfusion.
Allain JP
Transfus Clin Biol; 2001 Jun; 8(3):220-1. PubMed ID: 11499963
[TBL] [Abstract][Full Text] [Related]
5. International application of the incidence rate/window period model.
Glynn SA; Kleinman SH; Wright DJ; Busch MP;
Transfusion; 2002 Aug; 42(8):966-72. PubMed ID: 12385404
[No Abstract] [Full Text] [Related]
6. Inactivation of viruses in blood and plasma products.
Suomela H
Transfus Med Rev; 1993 Jan; 7(1):42-57. PubMed ID: 8431658
[No Abstract] [Full Text] [Related]
7. Can we improve the management of blood donors with nonspecific reactivity in viral screening and confirmatory assays?
Kiely P; Wood E
Transfus Med Rev; 2005 Jan; 19(1):58-65. PubMed ID: 15830328
[TBL] [Abstract][Full Text] [Related]
8. Reduction of virus load in blood donations by screening methods.
Kühnl P; Seidl S; Böhm BO
Curr Stud Hematol Blood Transfus; 1989; (56):9-22. PubMed ID: 2642787
[No Abstract] [Full Text] [Related]
9. Reducing the residual risk of transfusion-transmitted viruses: mini-pool or single-donation NAT?
Roth WK; Seifried E
Transfusion; 2001 Jun; 41(6):845-7. PubMed ID: 11399831
[No Abstract] [Full Text] [Related]
10. Kill and cure. The hope and reality of virus inactivation.
Prowse C
Vox Sang; 1994; 67 Suppl 3():191-6. PubMed ID: 7975491
[No Abstract] [Full Text] [Related]
11. Blood donations: justifying blood donor restrictions.
Spence JN; Iqbal FM
Br J Haematol; 2016 Sep; 174(5):822-3. PubMed ID: 26492347
[No Abstract] [Full Text] [Related]
12. Approaches to the reduction of viral infectivity in cellular blood components and single donor plasma.
Wagner SJ; Friedman LI; Dodd RY
Transfus Med Rev; 1991 Jan; 5(1):18-32. PubMed ID: 1802274
[No Abstract] [Full Text] [Related]
13. Current issues in transfusion therapy. 1. Risks of infection.
Coffin CM
Postgrad Med; 1986 Dec; 80(8):219-24. PubMed ID: 3786281
[TBL] [Abstract][Full Text] [Related]
14. Risks of blood transfusion-2002.
Sandler SG
Curr Opin Hematol; 2002 Nov; 9(6):509-10. PubMed ID: 12394173
[No Abstract] [Full Text] [Related]
15. The role of leukodepletion in the control of transfusion-transmitted disease.
Goldman M; Delage G
Transfus Med Rev; 1995 Jan; 9(1):9-19. PubMed ID: 7719040
[No Abstract] [Full Text] [Related]
16. The transfusion-transmitted viruses in blood transfusion.
Luban NL; Jubran RF
Adv Exp Med Biol; 2001; 489():1-12. PubMed ID: 11554584
[No Abstract] [Full Text] [Related]
17. Transfusion transmitted viral infections--recent developments in blood donor screening.
Yap PL
Postgrad Med J; 1990 Nov; 66(781):906-9. PubMed ID: 2176286
[No Abstract] [Full Text] [Related]
18. [Technological evolutions in blood donation screening and their impact on the residual risk].
Barlet V
Transfus Clin Biol; 2011 Apr; 18(2):292-301. PubMed ID: 21466969
[TBL] [Abstract][Full Text] [Related]
19. Safety of human albumin as a constituent of biologic therapeutic products.
McClelland DB
Transfusion; 1998 Jul; 38(7):690-9. PubMed ID: 9683109
[No Abstract] [Full Text] [Related]
20. Viruses.
Barbara J
Vox Sang; 2004 Jul; 87 Suppl1():95-7. PubMed ID: 15200615
[No Abstract] [Full Text] [Related]
[Next] [New Search]
